Filtered By:
Condition: Heart Attack
Drug: Vytorin
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 102 results found since Jan 2013.
Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial
CONCLUSIONS: In the TST trial (Treat Stroke to Target), targeting an LDL cholesterol of < 70 mg/dL with a combination of statin and ezetimibe compared with 100±10 mg/dL consistently reduced the risk of subsequent stroke.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01252875. URL: clinicaltrialsregister.eu; Unique identifier: EUDRACT2009-A01280-57.PMID:36154103 | DOI:10.1161/STROKEAHA.122.039728
Source: Atherosclerosis - September 26, 2022 Category: Cardiology Authors: Pierre Amarenco Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Byung-Chul Lee Philippa C Lavall ée Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research
More Than 50 Percent Reduction in LDL Cholesterol in Patients With Target LDL & lt;70 mg/dL After a Stroke
CONCLUSIONS: In this post hoc analysis of the TST trial, targeting an LDL cholesterol of <70 mg/dL reduced the risk of primary outcome compared with 100±10 mg/dL provided LDL cholesterol reduction from baseline was superior to 50%, thereby suggesting that the magnitude of LDL cholesterol reduction was as important to consider as the target level to achieve.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01252875; https://clinicaltrialsregister.eu; Unique identifier: EUDRACT2009-A01280-57.PMID:37376989 | DOI:10.1161/STROKEAHA.123.042621
Source: Atherosclerosis - June 28, 2023 Category: Cardiology Authors: Pierre Amarenco Philippa C Lavall ée Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Byung-Chul Lee Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research
Combination of a cholesterol-lowering statin and ezetimibe lowers risk of a heart attack or stroke
High cholesterol is a key culprit in the development of cardiovascular disease, the leading cause of death in the United States and many other developed countries. We know that lowering cholesterol helps prevent heart attacks and strokes. But an unanswered question remains: how low should you go? New research published online today in The New England Journal of Medicine suggests that lower is better.
Cholesterol and cardiovascular disease
Cholesterol travels through the bloodstream in two main particles: high-density lipoprotein (HDL) and low-density lipoprotein (LDL). HDL scavenges cholesterol from the bloodstream and fro...
Source: New Harvard Health Information - June 4, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Drugs and Supplements Heart Health cholesterol ezetimibe Source Type: news
Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients.
CONCLUSIONS: High potency lipid-lowering therapy effectively reduces the risk of recurrent IS in diabetic patients regardless of ATOR or EZ-SIM combination therapy.
PMID: 27270238 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - June 5, 2016 Category: Endocrinology Authors: Liu CH, Chen TH, Lin MS, Hung MJ, Chung CM, Cherng WJ, Lee TH, Lin YS Tags: J Clin Endocrinol Metab Source Type: research
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome The IMPROVE-IT Trial
ConclusionsLipid-lowering therapy with ezetimibe plus simvastatin improved clinical outcomes. Reductions in total PEP events, driven by reductions in MI and stroke, more than doubled the number of events prevented compared with examining only the first event. These data support continuation of intensive combination lipid-lowering therapy after an initial CV event. (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial [IMPROVE-IT]; NCT00202878)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - January 25, 2016 Category: Radiology Source Type: research
Studies support broader use of cholesterol-lowering statins
The latest guidelines used to determine who should take a cholesterol-lowering statin to prevent heart disease appear to be more accurate and cost-efficient than the previous guidelines. That’s according to two studies led by Harvard researchers, both published in this week’s Journal of the American Medical Association.
For many years, the main deciding factor in who needed to take a statin was the level of an individual’s harmful low-density lipoprotein cholesterol (LDL). Updated guidelines published in 2013 by the American College of Cardiology and the American Heart Association moved away from LDL and ...
Source: New Harvard Health Information - July 16, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements cholesterol high cholesterol statins Source Type: news
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
Publication date: Available online 2 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Marc P Bonaca, J Antonio Gutierrez, Christopher Cannon, Robert Giugliano, Michael Blazing, Jeong-Gun Park, Jennifer White, Andrew Tershakovec, Eugene BraunwaldSummaryBackgroundPolyvascular disease and type 2 diabetes are each associated with increased cardiovascular risk, but whether these risks are additive is unknown. In this exploratory analysis of a randomised trial, we explored the long-term cardiovascular risk associated with polyvascular disease, type 2 diabetes, and their combination in patients with acute corona...
Source: The Lancet Diabetes and Endocrinology - November 3, 2018 Category: Endocrinology Source Type: research
7 Myths About Cholesterol, Debunked
You may not recall every lab value from your last physical, but you probably remember one: Your cholesterol level.
If it’s higher than ideal, you’re not alone. According to the U.S. Centers for Disease Control and Prevention, between 2015 and 2018, almost 12% of U.S. adults ages 20 and up had high total cholesterol, defined as above 240 mg/dL. The type that physicians mostly worry about is LDL (or “bad”) cholesterol, which is one component of that total.
Why do doctors care so much about cholesterol? First, “it predicts risk,” says Dr. Jeffrey Berger, a cardiologist and director of the C...
Source: TIME: Health - June 19, 2023 Category: Consumer Health News Authors: Katherine Hobson Tags: Uncategorized freelance healthscienceclimate heart health Source Type: news
Ezetimibe provides particular benefit in patients with diabetes and recent acute coronary syndrome
(Brigham and Women's Hospital) According to the United States Centers for Disease Control and Prevention, over 800,000 Americans die each year from heart disease and stroke. Acute coronary syndrome, which includes heart attack and unstable angina, a condition that can lead to a heart attack, are among the leading causes of death and disability worldwide. In addition to lifestyle changes, medications that lower blood cholesterol are helpful in preventing future cardiac and vascular events, including heart attack and stroke.
Source: EurekAlert! - Medicine and Health - August 30, 2015 Category: Global & Universal Source Type: news
Rationale and design of REDUCE ‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic acid (EPA) reduces triglyceride‐rich lipoproteins without raising LDL‐C. Omega‐3s have postulated pleiotropic cardioprotective benefits beyond triglyceride‐lowering. To date, no large, multinational, randomized clinical trial has proved that lowering triglycerides on top of statin therapy improves cardiovascular ou...
Source: Clinical Cardiology - March 14, 2017 Category: Cardiology Authors: Deepak L. Bhatt, Ph. Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Michael Miller, Jean ‐Claude Tardif, Steven B. Ketchum, Ralph T. Doyle, Sabina A. Murphy, Paresh N. Soni, Rene A. Braeckman, Rebecca A. Juliano, Christie M. Ballantyne, Tags: TRIAL DESIGNS Source Type: research
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
CONCLUSIONS: Moderate- to high-quality evidence suggests that ezetimibe has modest beneficial effects on the risk of CVD endpoints, primarily driven by a reduction in non-fatal MI and non-fatal stroke, but it has little or no effect on clinical fatal endpoints. The cardiovascular benefit of ezetimibe might involve the reduction of LDL-C, total cholesterol and triglycerides. There is insufficient evidence to determine whether ezetimibe increases the risk of adverse events due to the low and very low quality of the evidence. The evidence for beneficial effects was mainly obtained from individuals with established atheroscler...
Source: Cochrane Database of Systematic Reviews - November 19, 2018 Category: General Medicine Authors: Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X Tags: Cochrane Database Syst Rev Source Type: research
Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized Controlled Trial.
CONCLUSIONS: LDL-C-lowering therapy with ezetimibe prevented cardiovascular events, suggesting the importance of LDL-C lowering for primary prevention in individuals aged ≥75 years with elevated LDL-C. Given the open label nature of the trial, its premature termination and issues with follow up, the magnitude of benefit observed should be interpreted with caution.
CLINICAL TRIAL REGISTRATION: URL: https://www.umin.ac.jp Unique identifier: UMIN000001988.
PMID: 31434507 [PubMed - as supplied by publisher]
Source: Circulation - August 21, 2019 Category: Cardiology Authors: Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, Urabe T, Uchida Y, Hayashi M, Yokota N, Nishida H, Otonari T, Arai T, Sakuma I, Sakabe K, Yamamoto M, Kobayashi T, Oikawa S, Yamashita S, Rakugi H, Imai T, Tanaka S, Ohashi Y, Kuwabara M, Ito H Tags: Circulation Source Type: research
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
In this interview with Dr. Lee Hooper we find out more about this new Cochrane review -Omega-3 fatty acids for the primary and secondary prevention of cardiovascular diseaseTell us about this Cochrane ReviewThere is a great deal of public belief in the cardiovascular benefits of omega-3 fats. Intakes of long-chain omega-3 fats in the US are higher from dietary supplements than foods. But public health advice differs across countries. The National Institute for Health and Clinical Excellence in the UK encourages people to eat oily fish intake (the major source of long-chain omega-3 f ats) but discourages supplementatio...
Source: Cochrane News and Events - February 5, 2020 Category: Information Technology Authors: Katie Abbotts Source Type: news
Effect of More Intensive LDL-C-Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis
Clin Ther. 2021 Jun 3:S0149-2918(21)00215-0. doi: 10.1016/j.clinthera.2021.04.019. Online ahead of print.ABSTRACTPURPOSE: The effect of more intensive LDL-C-lowering therapy (ILLT) on long-term cardiovascular outcomes during the early phase of acute coronary syndromes (ACSs) remains uncertain. We aimed to explore the influence of more intensive LDL-C-lowering therapyduring the early disease phase on long-term cardiovascular events among patients with ACSs.METHODS: Randomized controlled trials that focused on the effect of more ILLT during early-phase ACSs on long-term major adverse cardiac events (MACEs) were searched in e...
Source: Clinical Therapeutics - June 7, 2021 Category: Drugs & Pharmacology Authors: Siyao Jin Xiaolu Nie Yuxi Li Jinjie Yuan Yimin Cui Libo Zhao Source Type: research
